Press Releases July 30, 2026 08:30 AM

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

Lexicon Pharmaceuticals announces Q2 2026 financial results release and conference call scheduled for August 6, 2026.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
LXRX

Lexicon Pharmaceuticals, a biopharmaceutical company, will report its second quarter 2026 financial results on August 6, 2026 before the market opens. Management will host a conference call and webcast to discuss the results and provide a business update. The company focuses on developing drug candidates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders, and other cardiometabolic indications.

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
LXRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Second quarter 2026 financial results to be released on August 6, 2026.
  • Management will hold a conference call and webcast to discuss results and business updates.
  • Lexicon's pipeline includes drug candidates targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic and cardiometabolic disorders.

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. 

Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.

About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.   

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
[email protected]

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
[email protected]


Risks

  • Future financial results may not meet market expectations, leading to stock volatility.
  • Clinical development of drug candidates faces regulatory and clinical trial risks.
  • Market and economic conditions can impact biopharmaceutical sector performance and investor sentiment.

More from Press Releases

Baker Hughes and Venture Global Advance Next Phase of U.S. Gas Infrastructure Growth Sep 13, 2026 Axe Compute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Sep 11, 2026 EverCommerce Announces an Increase and Extension of its Share Repurchase Program Sep 11, 2026 Grupo Aeroportuario del Pacifico Announces the Execution of Bank Credit Facilities Totaling Ps. 8,000 Million Sep 11, 2026 Eastern International Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Sep 11, 2026